This content is machine translated Systemic lupus erythematosus What can belimumab and anifrolumab do? The monoclonal antibodies belimumab and anifrolumab are both approved for the treatment of systemic lupus erythematosus (SLE). Their response is considered to be highly effective. The point at which they…
This content is machine translated Rheumatoid arthritis in elderly patients Evidence-based therapy selection under the aspect of benefits and risks Current evidence suggests that the benefits of low-dose steroid therapy are greater than the harms in elderly patients with rheumatoid arthritis (RA). This is evident from the GLORIA study, in…
View Post 8 min This content is machine translated Psoriasis The era of biologics – a tour d’horizon through significant research decades The development of highly effective biologics was preceded by research efforts over several decades. Advances in immunopathogenetic and molecular genetic analyses contributed significantly to the generation of these innovative system…
View Post 13 min This content is machine translated Still's disease The Still syndrome in childhood and adulthood In 1896, a form of chronic infantile rheumatism was first noted in which symptoms of massive general inflammation were present in addition to arthritis. The disease was long referred to… CME-Test
View Post 3 min This content is machine translated Osteoporosis treatment according to needs What’s new? The American College of Physicians (ACP) published an updated 2023 guideline on drug therapy for patients with reduced bone density or osteoporosis. An extensive secondary analysis published last year has…
View Post 7 min This content is machine translated Myositides The most important guideline recommendations at a glance The German Society of Neurology (DGN) has issued an updated S2k guideline on myositis syndromes in 2022. In recent years, new therapeutic studies have helped improve treatment strategies. There have…
View Post 3 min This content is machine translated Plaque psoriasis New “Real World” Study on Tildrakizumab In a retrospective study of 30 patients with moderate to severe plaque psoriasis, the use of the IL-23 inhibitor tildrakizumab was shown to be effective and safe in clinical practice.…
View Post 6 min This content is machine translated Study Report Palmoplantar psoriasis – a diagnostic challenge Because many clinical and histopathologic features of palmoplantar psoriasis (PP) overlap with those of other dermatoses, differential diagnosis is far from trivial. With this in mind, a research team analyzed…
View Post 3 min This content is machine translated Plaque psoriasis Current 5-year data on secukinumab A long-term extension analysis of the ERASURE and FIXTURE studies recently published in the British Journal of Dermatology demonstrates the long-lasting efficacy and safety of secukinumab in patients with moderate-to-severe…
View Post 8 min This content is machine translated Translational medicine Psoriasis – from immunopathogenesis to successful therapy The innovative systemic treatments for psoriasis are a prime example of translational medicine. In a review published last year in the Journal of Investigative Dermatology, Prof. Peter van de Kerkhof,…
View Post 7 min This content is machine translated Medicalonline Long-term data on upadacitinib show a consistent safety profile and no new safety signals [1]. * With the exception of the already known higher herpes zoster and NMSC events and higher CPK levels.
